^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    INCA33890

    i
    Other names: INCA33890, INCA 33890, INCA-33890
    Associations

    News

    Trials
    Company:
    Incyte, Merus
    Drug class:
    PD1 inhibitor, TGF-β R2 kinase inhibitor
    Related drugs:
    Associations

    News

    Trials
    1m
    A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=245, Recruiting, Incyte Corporation | N=165 --> 245
    Enrollment change • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • PGR (Progesterone receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    HER-2 negative • ER negative • PGR negative
    |
    INCA33890
    over1year
    A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=165, Recruiting, Incyte Corporation | Not yet recruiting --> Recruiting | N=100 --> 165 | Trial completion date: May 2026 --> Dec 2026 | Trial primary completion date: May 2026 --> Dec 2026
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • PGR (Progesterone receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    HER-2 negative • ER negative • PGR negative
    |
    INCA33890
    over1year
    A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=100, Not yet recruiting, Incyte Corporation
    New P1 trial • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • PGR (Progesterone receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    HER-2 negative • ER negative • PGR negative
    |
    INCA33890
    over1year
    INCA33890, a novel PD-1×TGFꞵR2 bispecific antibody conditionally antagonizes TGFꞵ signaling in primary immune cells co-expressing PD-1 (AACR 2023)
    Additionally, in two independent PD-1 reporter assays, INCA33890 inhibited SHP recruitment and enhanced NFAT activation with a potency within an order of magnitude to that of pembrolizumab. Collectively, these results provide compelling data for an effective and specific approach to simultaneously antagonizing TGFβ and PD-1 signaling in tumors. Clinical development of INCA33890 in checkpoint inhibitor-resistant and other cancers has been initiated.
    PD(L)-1 Biomarker • IO biomarker • Immune cell
    |
    PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • CD34 (CD34 molecule) • TGFBR2 (Transforming Growth Factor Beta Receptor 2)
    |
    Keytruda (pembrolizumab) • INCA33890